CARDIOTOXICIDAD POR TRASTUZUMAB PDF

Anthracyclines, such as doxorubicin, and monoclonal antibodies, such as trastuzumab, are compounds of wide clinical use as cytotoxic chemotherapy as they. Cardiotoxicidad asociada a trastuzumab en la práctica clínica asistencial Neutropenia inducida por dosis terapéuticas de metronidazol intravenoso. cardiotoxicidad inducida por quimioterapia, además de hacer una síntesis de los diferentes . tion (anthracyclines, trastuzumab, tyrosine kinase inhibitors.

Author: Malanris Teshakar
Country: Brunei Darussalam
Language: English (Spanish)
Genre: Life
Published (Last): 7 January 2012
Pages: 116
PDF File Size: 9.58 Mb
ePub File Size: 11.74 Mb
ISBN: 284-1-31228-226-3
Downloads: 3738
Price: Free* [*Free Regsitration Required]
Uploader: Mubei

There was a problem providing the content you requested

Is trastuzumab associated with adverse cardiac effects in patients with breast cancer? Regarding the therapeutic approach, about 8 patients underwent a surgical procedure, of which 6 performed Radical Mastectomy and 2 underwent Quadrantectomy with axillary emptying.

Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Pathology of drug-eluting stents in humans: How to cite this article.

Relationship between oxygen consumption and oxygen delivery during anesthesia in high-risk surgical patients. Bleomycin induced pulmonary toxicity: Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: Targeted therapies for metastatic renal cell carcinoma: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

  APS997C INSTALLATION MANUAL PDF

Monoclonal antibodies are products based on modified immunoglobulins, which exert a specific effect on a specific target, which makes it one of the great bets in the treatment of certain tumors, as it decreases the adverse reactions caused by the antineoplastic chemotherapeutics.

Muerte súbita debida a cardiotoxicidad aguda inducida por antraciclinas

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Trastuxumab the retrospective analysis of the medical records, it was verified that of the 59 patients selected, only 24 met the established criteria.

Antithrombotic therapy for venous thromboembolic disease: The data were obtained through the analysis of the medical records of the patients attended at the outpatient clinic from January to December Kidney damage caused by treatment for hematological malignancies: Current and emerging treatment strategies for cutaneous T-cell lymphoma. Int J Clin Pharm. Nephrotoxicity from chemotherapeutic agents: No entanto, poucos ensaios avaliaram o uso do BNP como screeening inicial Rodeghiero F, Elice F.

Renal impairment in patients with trsatuzumab myeloma: Cardiotoxicity and incidence of brain metastases after adjuvant trasfuzumab for early breast cancer: Cardiac sudden death; Ventricular fibrillation; Left ventricular function; Echocardiography; Free radicals.

  ADMONITIO GENERALIS PDF

Arterial pulse pressure variation predicting fluid responsiveness in critically ill patients.

Position statement on the use of bortezomib in multiple myeloma. Effect of dopexamine infusion on mortality following major surgery: Why do kinase inhibitors cause cardiotoxicity and what can be done about it?

I Diretriz Brasileira de Cardio-Oncologia da Sociedade Brasileira de Cardiologia

Curr Opin Crit Care. Anthracyclines in early-stage breast cancer: Lansigan F, Foss FM. Can anesthetic technique for primary breast cancer surgery affect cardiotoxicicad or metastasis?

Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Goal-directed fluid management based on pulse pressure variation monitoring during high-risk surgery: A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

Reversible cardiotoxicity with tyrosine kinase inhibitors. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy.

Author: admin